Floatz logo

Eloxatin

Lenvatinib

First Hospital of China Medical UniversityActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Lenvatinib cohort.

Asset / SponsorPhaseRating
LENVATINIB
Sun Yat-sen University
Phase 2BB
Theprubicin
Sun Yat-sen University
Phase 2B
Ethiodized Oil
Sun Yat-sen University
Phase 2B
Tislelizumab
Zhejiang Cancer Hospital
Phase 2B
Pembrolizumab
National Taiwan University Hospital
Phase 2B

View all 14 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →